semaglutide and kidneys kidney disease FLOW clinical Trial (funded by Novo Nordisk): showed 24% reduction in Semaglutide Cuts Risk for Kidney

Results were similar when limited to patients with class 2 or 3 obesity. According to the authors, compared with patients prescribed GLP-1s or no treatment, patients who underwent MBS were more medically complex, with 25.7% having four or more comorbidities compared with 22.7% of GLP1 users and 16.0% of untreated patients

These medications differ in their mechanisms, administration routes, and clinical applications

While some places might market it for general energy boosts or weight loss, if your B12 levels are already normal, there's little scientific proof that these injections will give you a significant energy rush or help you lose weight

Understanding these underlying mechanisms is the basis for developing targeted therapeutic interventions and enhancing patient care [5]